8-K: Invivyd's PEMGARDA Shows Continued Neutralizing Activity Against Dominant COVID-19 Variants

Invivyd announced that PEMGARDA (pemivibart) continues to demonstrate neutralizing activity against the dominant SARS-CoV-2 variants KP.3.1.1 and LB.1, as well as other variants of interest.

Summary

• Invivyd has released new data showing that its antibody treatment, PEMGARDA (pemivibart), maintains its ability to neutralize the dominant COVID-19 variants KP.3.1.1 and LB.1.
• The CDC reports that KP.3.1.1 is the only major variant increasing in prevalence, accounting for 42.2% of circulating variants in the last two weeks of August.
• The company's pipeline candidate, VYD2311, also shows promising neutralization potency against the same contemporary viruses.
• Data has been submitted to the FDA to update the PEMGARDA Fact Sheet.
• PEMGARDA has demonstrated activity against 33 distinct SARS-CoV-2 variants over two years.
• The primary structure of the pemivibart epitope has remained intact across 99.59% of viral sequences since the original Omicron BA.1 variant.

Sentiment

Score: 7

Explanation: The document presents positive data regarding the continued effectiveness of PEMGARDA against new variants, which is a positive development. However, it also acknowledges limitations and risks, preventing a higher score.

Positives

• PEMGARDA continues to show neutralizing activity against current dominant COVID-19 variants.
• The company's pipeline candidate, VYD2311, also demonstrates strong neutralization potency.
• The data supports the continued use of PEMGARDA for pre-exposure prophylaxis.
• Invivyd's approach to viral surveillance and antibody engineering is proving effective.
• The structural integrity of the pemivibart binding site has been maintained across a high percentage of viral sequences.

Negatives

• The document mentions that certain SARS-CoV-2 viral variants may have substantially reduced susceptibility to PEMGARDA.
• There are limitations to the data supporting the benefits of PEMGARDA, including variability in cell-based EC50 value determinations.
• The emergency use authorization for PEMGARDA is only valid while the COVID-19 emergency declaration is in effect.

Risks

• The emergence of new SARS-CoV-2 variants could reduce the effectiveness of PEMGARDA.
• The FDA could revoke or revise the emergency use authorization for PEMGARDA.
• There are uncertainties related to the regulatory authorization or approval process for the company's product candidates.
• The company faces competition from other companies developing COVID-19 treatments.
• The company's ability to continue as a going concern is dependent on securing adequate funding.

Future Outlook

The company anticipates timely updates to the PEMGARDA Healthcare Providers Fact Sheet based on the new data submitted to the FDA. They also plan to continue developing new antibody medicines to address evolving viral threats.

Management Comments

• Robert Allen, Ph.D., Chief Scientific Officer, stated that Invivyd combines surveillance, predictive modeling, and antibody engineering to develop antibody medicines that demonstrate continued activity against evolving SARS-CoV-2.
• Marc Elia, Chairman of the Invivyd Board of Directors, noted that the data confirms ongoing PEMGARDA neutralizing activity against current circulating viral lineages.
• Mr. Elia also emphasized the importance of reliable antibody neutralization assessment and Invivyd's commitment to ensuring robust assessments of authentically manufactured pemivibart.

Industry Context

This announcement is significant as it addresses concerns about the effectiveness of antibody treatments against new COVID-19 variants. It highlights the ongoing need for continuous surveillance and development of new therapies to combat the evolving virus.

Comparison to Industry Standards

• The document references non-peer-reviewed reports assessing molecules similar to pemivibart, suggesting that there is a competitive landscape where other companies are developing similar treatments.
• The company emphasizes its use of a consistent, high-quality, independent, third-party pseudoviral system, which is a standard practice in the industry for assessing antibody neutralization.
• The document mentions that the company is following FDA guidance for data integrity, which is a key requirement for regulatory approval.

Stakeholder Impact

• Shareholders will likely view the continued effectiveness of PEMGARDA positively.
• Healthcare providers will have updated information on the effectiveness of PEMGARDA against current variants.
• Immunocompromised patients will benefit from the continued availability of PEMGARDA for pre-exposure prophylaxis.

Next Steps

• The company will continue its ongoing industrial virology efforts.
• The company will continue to develop new antibody medicines to address evolving viral threats.
• The company anticipates timely updates to the PEMGARDA Healthcare Providers Fact Sheet.

Key Dates

Keywords

PEMGARDA, pemivibart, COVID-19, SARS-CoV-2, monoclonal antibody, neutralizing activity, variant, KP.3.1.1, LB.1, VYD2311, EUA, FDA